Second FDA Recall Slams Blood Pressure Drug Amid Stubborn Quality Failures

The U.S. Food and Drug Administration (FDA) has just slapped an Indian manufacturer with its second major recall this year for a widely prescribed blood pressure medication. Inventia Healthcare Limited Chlorthalidone tablets, 25 mg, are being pulled from shelves again because they failed critical dissolution testing, meaning the pills might not work as intended for thousands of patients relying on them to manage high blood pressure. This latest Class II recall, affecting 13,567 bottles, underscores alarming quality control issues for a drug essential in preventing serious cardiovascular events. Dissolution testing is super important because it checks if a tablet breaks down correctly in the body to release its active ingredient; without proper breakdown, the drug's effectiveness drops significantly. For those managing hypertension, an ineffective Chlorthalidone dose could dangerously increase risks of heart attack, stroke, or kidney damage over time. The fact that this is Inventia's second recall for the same issue with the same medication since June 2026—totaling over 25,000 bottles recalled this year—raises serious questions about the company's manufacturing standards and the broader oversight of generic drug imports. Patients currently taking Chlorthalidone from Inventia Healthcare should not stop their medication abruptly, as doing so can be dangerous and cause blood pressure to spike; instead, they should contact their doctor or pharmacist immediately to check if their batch is affected and arrange for a safe replacement. This repeated failure will likely trigger intensified scrutiny from the FDA on Inventia Healthcare's manufacturing facilities and could prompt broader reviews of quality control measures for generic drugs produced overseas. Regulators and consumers alike will be watching closely to see what further actions are taken to ensure patient safety.